Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 were used with MF59 adjuvant as a candidate vaccine for a phase 1 safety and immunogenicity trial. Ten of 41 vaccinee serum samples displayed a neutralization titer of > or =1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 serum samples tested had a neutralization titer of > or =1:400 against human immunodeficiency virus (HIV)-HCV pseudotype, and 10 of 36 serum samples tested had a neutralization titer of > or =1:20 against cell culture-grown HCV genotype 1a. Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2.
Ray
Ranjit
R
Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St. Louis, Missouri, USA. rayr@slu.edu
Meyer
Keith
K
Banerjee
Arup
A
Basu
Arnab
A
Coates
Stephen
S
Abrignani
Sergio
S
Houghton
Michael
M
Frey
Sharon E
SE
Belshe
Robert B
RB
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D057134:Antibodies, Neutralizing / Q000097:blood; D005822:Genetic Vectors; D006678:HIV / Q000235:genetics; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D011136:Polysorbates / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage; D018116:Vesiculovirus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; C087035:E1 protein, Hepatitis C virus; D018937:Hepatitis C Antibodies; C089950:MF59 oil emulsion; D011136:Polysorbates; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines; C091015:glycoprotein E2, Hepatitis C virus; D013185:Squalene